Skip to content
Screener

Perspective Therapeutics CATX Total Operating Expenses

Total Operating Expenses at other companies

CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$25.2M+26.3%
Immunome logo
ImmunomeIMNM
$78.14M+54.7%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$48.77M+1.8%
Monopar Therapeutics logo
Monopar TherapeuticsMNPR
$5.23M+62.2%
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC
$1.44B+8.3%
Varex Imaging Corporation logo
Varex Imaging CorporationVREX
$53.9M-63.6%

Other financials

Income statement

See full
Revenue$2.2M+27.3%
Gross profit$738.0K+78.3%
Operating income-$29.3M-21.7%
Net income-$26.8M-24.7%
EPS (diluted)-$0.22+24.1%

Balance sheet

See full
Cash & equivalents$48.5M+68.1%
Total debt$3.9M+11.1%
Total equity$323.9M+21.9%
Total assets$392.0M+26.2%

Cash flow

See full
Operating cash flow-$20.7M-3.5%
CapEx$14.2M+1,284%
Free cash flow-$34.8M-66.1%

Valuation

See full
Market cap$342.14M+25.3%
Enterprise value$297.56M+20.1%

Profitability

See full
Gross margin33.1%-7.1pp
Operating margin-292.7%-553pp
Net margin-218.4%-781pp

Returns & leverage

See full
Return on equity-39.5%+14.0pp
Debt / equity0.0×
Current ratio6.6×-8.5×

Where this comes from

Reported directly by Perspective Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: Perspective Therapeutics’s 10-Q, filed August 10, 2026.

Filed
Aug 10, 2026, 4:34 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-342512
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
Operating expenses:
Research and development21,54416,62042,91630,952
General and administrative7,7957,70914,78015,551
Total operating expenses29,33924,32957,69646,503
Operating loss(29,258)(24,039)(57,539)(45,871)
Non-operating income (expense):
Interest income2,3472,1594,5444,543
Interest and other expense(71)(119)(176)(247)

ITEM 1 - FINANCIAL STATEMENTS

FAQ

What is Perspective Therapeutics's total operating expenses?
Perspective Therapeutics (CATX) reported total operating expenses of $29.34M in Q2 2026.
How has Perspective Therapeutics's total operating expenses changed year-over-year?
Perspective Therapeutics's total operating expenses increased by 20.6% year-over-year, from $24.33M to $29.34M.
What is the long-term trend for Perspective Therapeutics's total operating expenses?
Over 4 years (2021 to 2025), Perspective Therapeutics's total operating expenses has grown at a 91.2% compound annual growth rate (CAGR), from $8.57M to $114.45M.
What does total operating expenses mean?
The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.

Ask your AI about Perspective Therapeutics's total operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude